Caribou Biosciences, Inc. $CRBU Shares Purchased by Aberdeen Group plc

Key Points

• Aberdeen Group plc increased its holdings in Caribou Biosciences by 126.5%, acquiring an additional 229,657 shares in the first quarter, bringing its total ownership to 411,144 shares valued at $375,000.
• Wall Street analysts have mixed ratings for Caribou Biosciences, with three giving it a Buy rating and a consensus target price of $6.67, while a recent report downgraded it to a sell.
• Caribou Biosciences reported a revenue of $2.67 million last quarter, exceeding expectations, and plans to post -1.64 earnings per share for the current year.

Aberdeen Group plc increased its stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 126.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 411,144 shares of the company's stock after purchasing an additional 229,657 shares during the period. Aberdeen Group plc owned 0.44% of Caribou Biosciences worth $375,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of CRBU. Wells Fargo & Company MN raised its holdings in Caribou Biosciences by 112.8% in the 4th quarter. Wells Fargo & Company MN now owns 91,988 shares of the company's stock valued at $146,000 after acquiring an additional 48,759 shares during the last quarter. Envestnet Asset Management Inc. boosted its position in Caribou Biosciences by 43.4% during the 4th quarter. Envestnet Asset Management Inc. now owns 46,301 shares of the company's stock worth $74,000 after purchasing an additional 14,021 shares during the period. Russell Investments Group Ltd. boosted its position in Caribou Biosciences by 859.0% during the 4th quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company's stock worth $38,000 after purchasing an additional 21,416 shares during the period. Barclays PLC boosted its position in Caribou Biosciences by 12.0% during the 4th quarter. Barclays PLC now owns 145,417 shares of the company's stock worth $231,000 after purchasing an additional 15,578 shares during the period. Finally, MetLife Investment Management LLC boosted its position in Caribou Biosciences by 60.0% during the 4th quarter. MetLife Investment Management LLC now owns 24,404 shares of the company's stock worth $39,000 after purchasing an additional 9,148 shares during the period. 77.51% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Caribou Biosciences from a "sell" rating to a "hold" rating in a research report on Sunday. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $6.67.

Caribou Biosciences Stock Performance

Shares of Caribou Biosciences stock traded up $0.06 during trading on Thursday, reaching $2.04. The company had a trading volume of 200,790 shares, compared to its average volume of 1,323,531. The company has a market cap of $189.50 million, a price-to-earnings ratio of -1.14 and a beta of 2.55. The firm's fifty day moving average is $1.78 and its 200-day moving average is $1.28. Caribou Biosciences, Inc. has a fifty-two week low of $0.66 and a fifty-two week high of $3.00.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.05. The business had revenue of $2.67 million for the quarter, compared to analyst estimates of $1.64 million. Caribou Biosciences had a negative net margin of 1,800.93% and a negative return on equity of 62.35%. On average, research analysts anticipate that Caribou Biosciences, Inc. will post -1.64 EPS for the current fiscal year.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.